Effect of Intraarticular Ozone, Prolotherapy or Dexmedetomidine in Pain Limitation in Knee Osteoarthritis

Tanta University

Status: Completed

Conditions: Intraarticular; Prolotherapy; Dexmedetomidine; Ozone; Knee Osteoarthritis; Pain

Treatments: Drug: Dexmedetomidine; Drug: Dextrose prolotherapy; Drug: Ozone

Study type: Interventional

Funder types: Other

Identifiers

NCT06909305

35148/12/21

Details and patient eligibility

About

This study aimed to compare intraarticular ozone injection, prolotherapy, or dexmedetomidine effectiveness in knee osteoarthritis patients.

Full description

Osteoarthritis (OA) is a heterogeneous group of disorders of different etiologies with similar biological, morphological, and clinical manifestations and outcomes. The intraarticular injection has been recommended to alleviate the pain in the knee joint.

Ozone therapy has long been used in the management of OA. Furthermore, it has been shown to not cause a significant inflammation process or cartilage degradation. Prolotherapy is a procedure where a natural irritant is injected into the soft tissue of an injured joint. Dexmedetomidine is a selective α2-adrenergic agonist with considerable sedative and analgesic actions.

Enrollment: 60 patients

Sex: All

Ages: 30 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age from 30 to 65 years.
• Both genders.
• Patients diagnosed with stage 1-3 osteoarthritis according to the Kellgren-Lawrence Classification System (K-L).

Exclusion criteria

• Patient refusal.
• History of knee trauma within the past month.
• Rheumatic disease.
• Pregnancy.
• Any surgical intervention of the knee.
• Severe cardiovascular disease.
• Morbid obese patients (body mass index (BMI) of >35 kg/m2).
• Local infection at the site of injection.
• Bleeding diathesis.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 3 patient groups

Ozone group

Experimental group

Description:

Patients received intraarticular ozone injection.

Treatment:

Drug: Ozone

Dextrose prolotherapy group

Experimental group

Description:

Patients received intraarticular dextrose prolotherapy injection.

Treatment:

Drug: Dextrose prolotherapy

Dexmedetomidine group

Experimental group

Description:

Patients received intraarticular dexmedetomidine injection.

Treatment:

Drug: Dexmedetomidine